Laboratory Products
New Distributor of Cryopreserved Terminally Differentiated Human Hepatic Cells
Jan 10 2012
Merck Millipore recently announced that the company will be the initial distributor of HepaRG(TM) human hepatic cells from Biopredic. HepaRG cells, derived from a hepatocellular carcinoma, are supplied as cryopreserved, terminally differentiated cells and express major liver specific functions including Cytochrome P450 enzymes and drug transporters. HepaRG cells provide a number of advantages over primary hepatocytes and liver slices for
characterisation of the uptake, metabolism, and disposition of drug candidates, drug discovery, and high throughput screening. The supply of primary cells and tissue can be unpredictable and other transformed lines such as HepG2 have not gained widespread use due to loss of specific liver functions such as Cytochrome P450, thus impacting the proper assessment of toxicity.
“With more than 900 drugs having been implicated in causing liver injury and toxicity, there is a need for more accurate prediction of hepatic cytotoxicity and genotoxicity in humans,” noted Umesh A. Patel, PhD, Director, Lead Discovery. “While in vitro human liver preparations offer the most pertinent models, availability and inter-donor variability are significant drawbacks. In contrast, HepaRG(TM) cells reproducibly express the activities drug metabolising enzymes and transporters to facilitate ADME/tox studies.”
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
Microbiology Society Annual Conference 2024
Apr 08 2024 Edinburgh 2024
Apr 09 2024 Munich, Germany
Apr 10 2024 Helsinki, Finland
Analytica Anacon India & IndiaLabExpo
Apr 15 2024 Mumbai, India
Apr 16 2024 Moscow, Russia